Real-world progression-free survival among patients with newly diagnosed advanced ovarian cancer: Does maintenance therapy work?
In an ideal world every patient with ovarian cancer would have optimal treatment. However, there is often a difference between the rhetoric and reality.
Personalised cancer therapy is becoming more frequent including maintenance treatment following surgery and chemo, with monoclonal antibodies or enzyme inhibitors. This study looked at the real experiences of women with advanced ovarian cancer.
463 women were included in this retrospective study, all ovarian cancer patients at the same centre of excellence. Treatment began during the period 2016-2020. Only 21% of the women received maintenance therapy. Those patients who did had a 29% lower risk of progression, with a median improvement in progression free survival of 4 months compared to those who did not.
No comments:
Post a Comment